Welcome to our dedicated page for ARTIVION SEC filings (Ticker: AORT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Artivion, Inc. filings document the regulatory record for a medical device company focused on aortic disease and related tissue preservation services. Recent Form 8-K disclosures furnish quarterly and annual operating results, clinical and regulatory updates, material agreements, and capital-structure matters, including credit-facility amendments and secured delayed draw term loan financing.
Proxy materials describe annual meeting voting, board governance, executive compensation, and shareholder matters. Other current reports document leadership appointments, material contracts, facilities-related agreements tied to the company’s operations, and disclosures connected to products such as aortic stent grafts, On-X mechanical heart valves, surgical sealants, and implantable cardiac and vascular human tissues.
ARTIVION, INC. VP and Chief Accounting Officer Amy Horton reported both a stock award and a small share sale. She received 7,475 shares of common stock on March 2, 2026 as part of a performance stock unit grant made on February 28, 2025, with additional portions scheduled to vest in 2027 and 2028 if she remains employed on those dates. On March 3, 2026, 901 shares were sold at an average price of $37.7756 to cover tax withholding obligations arising from the vesting of performance stock units, and this "sell to cover" was described as non-discretionary. After the sale, she directly held 139,088 shares of common stock.
ARTIVION, INC. executive Jean F. Holloway, SVP and General Counsel, reported equity compensation activity and related tax sales in company stock. She acquired 27,795 shares of common stock on a grant or award basis at $0.00 per share, tied to performance stock units granted in February 2025, with remaining portions scheduled to vest in February 2027 and February 2028 subject to continued employment. Following this vesting, she sold 3,843 shares at an average price of $37.7756 on March 3, 2026 and 8,962 shares at $38.00 on March 4, 2026 solely to cover tax withholding obligations under a “sell to cover” arrangement, which the filing states is not a discretionary transaction. After these transactions, she directly owned 185,095 shares of Artivion common stock.
ARTIVION, INC. senior vice president Stanton Marshall S. reported two stock transactions involving company common shares. He acquired 21,838 shares on a grant/award basis at $0.0000 per share as part of performance stock units granted in February 2025. According to the award terms, additional portions of this grant are eligible to vest on February 28, 2027 and February 28, 2028, subject to continued employment on each vesting date. On March 3, 2026, 2,149 shares were sold at an average price of $37.7756 per share to cover tax withholding obligations through a sell-to-cover transaction, which the company notes was not a discretionary sale. After these transactions, Marshall directly owned 60,097 shares of Artivion common stock.
Artivion, Inc. Chief Commercial Officer John E. Davis reported two equity transactions in company common stock. On March 2, 2026, he acquired 28,845 shares at $0.00 per share, issued upon vesting of performance stock units from a February 2025 grant. On March 3, 2026, 4,573 shares were sold at an average price of $37.7756 per share to cover tax withholding obligations in a non-discretionary “sell to cover” transaction. Following these movements, Davis held 230,794 shares of Artivion common stock directly.
Artivion, Inc. executive Lance A. Berry reported equity compensation activity and a related tax sale of shares. He acquired 40,874 shares of common stock on a grant or award basis at a price of $0.0000 per share on March 2, 2026, connected to performance stock units granted on February 28, 2025. One third of these units were issued on March 2, 2026, with the remaining thirds scheduled to be eligible to vest on February 28, 2027 and February 28, 2028, assuming continued employment.
On March 3, 2026, 6,316 shares of common stock were sold in an open-market transaction at an average price of $37.7756 per share to cover tax withholding obligations arising from the vesting of these performance stock units. The filing states this “sell to cover” transaction was undertaken to satisfy tax obligations and does not represent a discretionary trade. Following these transactions, Berry directly held 210,827 shares of Artivion common stock.
Artivion, Inc. President & CEO James P. Mackin reported both an equity award and a related share sale. He acquired 116,948 shares of common stock on a grant/award basis at $0.00 per share following the vesting of performance stock units from a February 2025 grant.
On the next trading day, he sold 17,887 shares of common stock at an average price of $37.7756 per share in an open‑market transaction specifically to cover tax withholding obligations under a “sell to cover” arrangement, characterized as a non‑discretionary transaction. Following these transactions, he directly owned 947,275 shares of Artivion common stock.
Jean F Holloway reports proposed sales of common stock under Rule 144. The notice lists recent transactions including 03/02/2026 sale of 2,183 shares for $83,008.36, 02/24/2026 sale of 1,668 shares for $59,535.92, and 02/23/2026 sale of 3,079 shares for $115,733.45.
AORT: Section 144 notice reporting restricted stock vesting and recent insider sales.
The filing lists 6,316 common shares associated with a restricted stock vesting event on 02/27/2026. It also discloses three sales by Lance Berry: 4,981 shares (proceeds $187,223.34) on 02/23/2026, 4,885 shares (proceeds $160,082.66) on 02/24/2026, and 5,178 shares (proceeds $196,892.93) on 03/02/2026.
John E. Davis reported insider share transactions under Form 144 relating to AORT common stock. The filing lists proposed restricted-stock vesting of 4,573 shares on 02/27/2026 and discloses sales executed in the prior three months: 3,773 shares on 02/23/2026 ($141,817.64), 2,075 shares on 02/24/2026 ($74,062.77), and 2,784 shares on 03/02/2026 ($105,861.32).
AORT reported proposed insider sales of Common Stock under Form 144 by Jean F. Holloway. The filing lists sales on 02/23/2026 of 3,079 shares for $115,731.92, on 02/24/2026 of 1,668 shares for $59,535.76, and on 03/02/2026 of 2,183 shares for $83,008.36. The broker listed is Fidelity Brokerage Services LLC with an execution reference date of 03/03/2026.